Scarica l'app Stockscreener
1.665
6.83%
0.105
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Precedente Chiudi:
$1.56
Aprire:
$1.6
Volume 24 ore:
4.57M
Relative Volume:
0.91
Capitalizzazione di mercato:
$265.25M
Reddito:
-
Utile/perdita netta:
$-110.78M
Rapporto P/E:
-1.5561
EPS:
-1.07
Flusso di cassa netto:
$-75.59M
1 W Prestazione:
-32.80%
1M Prestazione:
+13.37%
6M Prestazione:
+8.92%
1 anno Prestazione:
-70.92%
Intervallo 1D:
$1.5914
$1.695
Intervallo di 1 settimana:
$1.55
$1.969
Portata 52W:
$1.15
$6.77
Humacyte Inc Stock (HUMA) Company Profile
Nome
Humacyte Inc
Settore
Industria
Telefono
919-313-9633
Indirizzo
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Confronta HUMA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.67 | 292.14M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.18 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.85 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.65 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
808.25 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.21 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-27 | Iniziato | Barclays | Overweight |
| 2025-05-14 | Ripresa | H.C. Wainwright | Buy |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2023-12-11 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-14 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Downgrade | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Iniziato | Cowen | Outperform |
| 2021-09-24 | Iniziato | Oppenheimer | Outperform |
| 2021-09-22 | Iniziato | BTIG Research | Buy |
| 2021-09-16 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Humacyte Inc Borsa (HUMA) Ultime notizie
Should I hold or sell Humacyte Inc. Equity Warrant stock in 20252025 Top Decliners & AI Driven Stock Reports - newser.com
Is Humacyte Inc. Equity Warrant forming a bottoming baseGap Down & Fast Moving Stock Watchlists - newser.com
Understanding Humacyte Inc. Equity Warrant’s price movementMarket Performance Summary & Fast Entry High Yield Stock Tips - newser.com
Live market analysis of Humacyte Inc. Equity WarrantWeekly Earnings Recap & AI Enhanced Trading Signals - newser.com
Applying sector rotation models to Humacyte Inc. Equity Warrant2025 Price Action Summary & Smart Investment Allocation Tips - newser.com
Is Humacyte Inc. stock trading near support levelsBreakout Watch & Low Risk High Win Rate Picks - newser.com
Applying chart zones and confluence areas to Humacyte Inc.July 2025 Movers & High Yield Equity Trading Tips - newser.com
Using fundamentals and technicals on Humacyte Inc. Equity WarrantEarnings Recap Summary & Risk Managed Investment Entry Signals - newser.com
Relative strength of Humacyte Inc. in sector analysisMarket Movers & Long-Term Growth Plans - newser.com
Will Humacyte Inc. stock gain from government policiesJobs Report & Verified Short-Term Plans - newser.com
Can a trend reversal in Humacyte Inc. Equity Warrant lead to recoveryTrade Entry Summary & Entry Point Strategy Guides - newser.com
Humacyte (HUMA) Is Down 25.7% After Reporting Strong Symvess Trauma Results and Completing $60M Equity Raise - Yahoo Finance
Humacyte shares sink as it announces pricing of $60M direct offering - MSN
Advanced analytics toolkit walkthrough for Humacyte Inc.Take Profit & Long-Term Capital Growth Strategies - newser.com
Top chart patterns to watch in Humacyte Inc.Earnings Overview Summary & AI Powered Market Entry Ideas - newser.com
Building trade automation scripts for Humacyte Inc.July 2025 PreEarnings & Fast Gaining Stock Reports - newser.com
Real time social sentiment graph for Humacyte Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - newser.com
Published on: 2025-10-10 04:58:04 - newser.com
Is Humacyte Inc. stock poised for growthWeekly Trade Report & Safe Capital Growth Plans - newser.com
Humacyte Announces $60M Stock and Warrants Offering - MSN
Published on: 2025-10-09 06:28:01 - newser.com
Is Humacyte Inc. Equity Warrant stock positioned for digital transformation2025 Retail Activity & Real-Time Volume Triggers - newser.com
Weiss Ratings Reiterates Sell (E+) Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte, Inc.Common Stock (NQ: - FinancialContent
Combat Trauma Study Results Might Change The Case For Investing In Humacyte (HUMA) - simplywall.st
What analysts say about Humacyte Inc stockRisk Mitigation Techniques & Fast Growing Investment Plans - earlytimes.in
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors - Yahoo Finance
Investors Buy High Volume of Call Options on Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte: Shares Tank On Fundraising NewsWhat You Need To Know (NASDAQ:HUMA) - Seeking Alpha
Humacyte Gains 43%, Insider Trades Reap Benefit - Yahoo
Humacyte (HUMA) Valuation in Focus After Encouraging Ukraine Trauma Results and New Patent Milestone - simplywall.st
Humacyte shares plunge after announcing $60 million registered direct offering - MSN
Humacyte Prices $60 Million Oversubscribed Registered Direct Offering; Shares Tumble - MarketScreener
Humacyte prices 28.4M shares at $2.11 in registered direct offering - TipRanks
Humacyte secures $60 million in registered direct offering - Investing.com
Humacyte stock tumbles after $60 million registered direct offering - Investing.com
Humacyte announces pricing of $60.0 million oversubscribed registered direct offering - MarketScreener
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering - MarketScreener
Is Humacyte Inc a good long term investmentMean Reversion Trades & Breakthrough Stock Performance - earlytimes.in
Humacyte rises after positive data from humanitarian study of Symvess - MSN
HUMA: D. Boral Capital Maintains 'Buy' Rating with $25 Price Tar - GuruFocus
Humacyte's (HUMA) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Humacyte reports positive long-term results for vascular trauma device - Investing.com India
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™ - The Manila Times
Humacyte, Inc. Reports Zero Infections and High Patency Rates for Symvess in Military Medicine Journal Publication on Wartime Vascular Trauma Treatment - Quiver Quantitative
87.1% patency in 17 patients — Humacyte's Symvess shows zero infections, amputations or deaths - Stock Titan
How to monitor Humacyte Inc. with trend dashboardsEarnings Recap Summary & AI Enhanced Trading Alerts - newser.com
Why Humacyte Inc. stock remains undervaluedTrade Volume Summary & High Conviction Buy Zone Alerts - newser.com
How to integrate Humacyte Inc. Equity Warrant into portfolio analysis toolsPortfolio Update Summary & Safe Capital Investment Plans - newser.com
Developing predictive dashboards with Humacyte Inc. dataJuly 2025 Update & High Yield Stock Recommendations - newser.com
Humacyte Inc Azioni (HUMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Humacyte Inc Azioni (HUMA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dougan Brady W | Director |
Aug 18 '25 |
Sale |
1.83 |
549,360 |
1,005,329 |
1,691,685 |
| Dougan Brady W | Director |
Aug 20 '25 |
Sale |
1.58 |
591,685 |
934,862 |
0 |
| Niklason Laura E | President, CEO and Director |
Aug 19 '25 |
Sale |
1.63 |
1,100,000 |
1,793,000 |
591,685 |
| Niklason Laura E | President, CEO and Director |
Aug 18 '25 |
Sale |
1.83 |
549,360 |
1,005,329 |
1,691,685 |
| Niklason Laura E | President, CEO and Director |
Aug 20 '25 |
Sale |
1.58 |
591,685 |
934,862 |
0 |
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):